VCEL Q2 2021 Earnings — Vericel Corporation Revenue & Financial Results | Market Cap Arena

VCELVericel Corporation

$2B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$40M+97.5% YoY

Gross Profit

$27M68.1% margin

Operating Income

-$4M-9.4% margin

Net Income

-$4M-9.6% margin

EPS (Diluted)

$-0.08

QoQ Revenue Growth

+14.3%

Cash Flow

Operating Cash Flow

$5M

Free Cash Flow

$3M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$222M

Total Liabilities

$71M

Stockholders' Equity

$151M

Cash & Equivalents

$52M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$40M	$20M	+97.5%
Gross Profit	$27M	$11M	+137.0%
Operating Income	-$4M	-$8M	+55.4%
Net Income	-$4M	-$8M	+54.2%

Revenue Segments

MACI Implants and Kits, and Epicel

$39M100%